Topics

Articles

The conference will focus on the full breadth of commercialization strategies and operations. 

Pharma Commercialization Experts to Converge at Access Insights Conference 2023

Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).

Adalimumab Biosimilar Now Available at Significant Discount to Humira

The debate continues as to how government payers should weigh covering
healthcare needs versus other budget items.

Affordability: Who's Responsible?

These programs can negatively impact patients trying to reach their deductible.

Time to Ax Copay Accumulators?

The trend is continuing for brands and even for some specialty products.

Return of Cash Pay for Drugs

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Study Highlights PBMs’ Role in Drug Prices

Nearly 96% of respondents say that this is an issue affecting their respective pharmacy. 

Pharmacy Technician Certification Board Survey Finds Drug Shortages Impact Majority of Pharmacies

Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes. 

Select Health, Mark Cuban Cost Plus Drug Company Partner on Lowering Prescription Drug Costs

How drugmakers can navigate the program’s pricing challenges and regulatory developments.

A 340B Navigation Guide for Pharmaceutical Manufacturers

Conditions require a disciplined approach to drug pricing.

Market Access and Pricing